Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 26.32M | 61.89M | [{"date":"2024-12-31","value":42.52,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Income | (26.32M) | (61.89M) | [{"date":"2024-12-31","value":-2631700000,"profit":false},{"date":"2025-12-31","value":-6188900000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 1.53M | (86.00K) | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-5.62,"profit":false}] | |||
| Pre-Tax Income | (24.79M) | (61.98M) | [{"date":"2024-12-31","value":-2478600000,"profit":false},{"date":"2025-12-31","value":-6197500000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (24.79M) | (61.98M) | [{"date":"2024-12-31","value":-2478600000,"profit":false},{"date":"2025-12-31","value":-6197500000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (24.79M) | (61.98M) | [{"date":"2024-12-31","value":-2478600000,"profit":false},{"date":"2025-12-31","value":-6197500000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
| ETRA | |
|---|---|
| Current Ratio | 7.37 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| ETRA | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| ETRA | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 1.25 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.25 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| ETRA | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Electra Therapeutics, Inc. Common stock (ETRA) share price today is $9.421
Yes, Indians can buy shares of Electra Therapeutics, Inc. Common stock (ETRA) on Vested. To buy
Yes, you can purchase fractional shares of Electra Therapeutics, Inc. Common stock (ETRA) via the Vested app. You can start investing in Electra Therapeutics, Inc. Common stock (ETRA) with a minimum investment of $1.
You can invest in shares of Electra Therapeutics, Inc. Common stock (ETRA) via Vested in three simple steps:
The 52-week high price of Electra Therapeutics, Inc. Common stock (ETRA) is $15.5. The 52-week low price of Electra Therapeutics, Inc. Common stock (ETRA) is $6.87.
The price-to-earnings (P/E) ratio of Electra Therapeutics, Inc. Common stock (ETRA) is
The price-to-book (P/B) ratio of Electra Therapeutics, Inc. Common stock (ETRA) is 0.00
The dividend yield of Electra Therapeutics, Inc. Common stock (ETRA) is 0.00%
The market capitalization of Electra Therapeutics, Inc. Common stock (ETRA) is $501.51M
The stock symbol (or ticker) of Electra Therapeutics, Inc. Common stock is ETRA
Consider the share price of Electra Therapeutics, Inc. Common stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Electra Therapeutics, Inc. Common stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Electra Therapeutics, Inc. Common stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Electra Therapeutics, Inc. Common stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Electra Therapeutics, Inc. Common stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Electra Therapeutics, Inc. Common stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied
